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Abstract  
Purpose: The cure rate in Hodgkin Lymphoma is high, but the response along the treatment is still 
unpredictable and is highly variable among patients. Detecting those patients that do not respond to the 
treatment at early stages could bring improvements in their treatment. This research tries to identify the 
main biological prognostic variables currently gathered at diagnosis, and designing a simple machine 
learning methodology to help physicians improving the treatment response assessment. Methods: We 
carried out a retrospective analysis of the response to treatment for a cohort of 263 Caucasians who were 
diagnosed with Hodgkin Lymphoma in Asturias (Spain). For that purpose, we used a list of 35 clinical 
and biological variables that are currently measured at diagnosis, before any treatment begins. To 
establish the list of most discriminatory prognostic variables for the treatment response we designed a 
machine learning approach based on two different feature selection methods (Fisher’s ratio and 
Maximum Percentile Distance) and recursive feature elimination using a nearest-neighbor classifier (k-
NN). The weights of the k-NN classifier are optimized using different terms of the confusion matrix (true 
and false positive rates) in order to minimize risk in the decisions. Results and conclusions: We found 
that the optimum strategy to predict treatment response in Hodgkin lymphoma consists in solving two 
different binary classification problems, discriminating first if the patient is in progressive disease, if not, 
then discerning among complete and partial remission. Serum Ferritin turned to be the most 
discriminatory variable in predicting treatment response, followed by Alanine Aminotransferase and 
Alkaline Phosphate. The importance of these prognostic variables suggests a close relationship between 
inflammation, iron overload, liver damage and the extension of the disease. 
Keywords: Hodgkin Lymphoma, treatment response, machine learning, Serum Ferritin (SF), Alanine 
Aminotransferase (ALT), Alkaline Phosphate (ALP). 
PURPOSE 
Lymphoma is the most common blood cancer and comprises two types: 
Hodgkin Lymphoma (HL) and non-Hodgkin Lymphoma. HL is characterized by the 
presence of the so-called malignant Reed-Sternberg cells, surrounded by an 
inflammatory infiltrate consisting of lymphocytes, neutrophils, eosinophils, plasma 
cells, macrophages and fibroblasts, constituting a model of interaction of tumor cells 
with their microenvironment. Components of inflammatory background are associated 
with classical HL: the presence of tumor-infiltrating lymphocytes is a negative 
prognostic factor for survival in these patients [1]. This kind of cancer is most 
commonly diagnosed in young adults between the ages of 15 and 35 and in older adults 
over 50. The cure rate in HL patients is high, but the response along the treatment is still 
unpredictable and varies from patient to patient. Besides, small minority is resistant or 
relapses before treatment. Detecting those patients with a poor prognosis at early stages 
(diagnosis) could bring improvements in their treatment and prognosis. 
There was an international effort to identify prognostic factors to accurately 
predict the development and treatment in HL, mainly in patients with advanced HL 
stage. The adverse prognostic factors identified were: male older than 45, stage IV 
disease, hemoglobin lower than 10.5 g/dl, lymphocyte count lower than 600 /µl (or less 
than 8%), albumin lower than 4.0 g/dl, and white blood count greater than 15,000 /µl [2, 
3]. Other studies also took into account mixed-cellularity or lymphocyte-depleted 
histologies, the presence of B symptoms or high erythrocyte sedimentation rate, and 
bulky disease as adverse prognostic factors [4, 5]. Moreover, disease extensions 
measured by Computed Tomography (CT), and early response to treatment measured 
by Positron Emission Tomography (PET) have demonstrated a powerful prognostic 
ability [6, 7]. 
Several research works highlighted the importance of the identification of 
prognostic variables to predict patients who will suffer relapse and the adaptation of 
treatments to individual risks [8-11]. Particularly, the result of the treatment 
optimization provoked some criteria modification, with the disappearance of some 
factors that were considered of poor prognosis and with the proposal of new ones that 
allowed establishing groups with differing risks of relapse and differentiated treatment.  
In this manuscript we inferred prognostic variables for HL treatment response 
using clinical data and machine learning techniques in a retrospective study for a cohort 
of 263 Caucasians. For this purpose we designed a methodology to find the shortest list 
of clinical variables providing the highest predictive accuracy for the Hodgkin 
Lymphoma first line treatment response (at diagnosis). We found that the best way of 
addressing this problem is to proceed in two steps: comparing first the complete/partial 
remission hypothesis against progressive disease hypothesis, and secondly 
differentiating between complete and partial remission in case it proceeds. Serum 
Ferritin (SF) turned to be the most important prognostic variable, achieving cross-
validation predictive accuracies higher than 90%. Ferritin concentrations increase 
drastically in the presence of an infection or cancer [12]. Our study has also showed the 
importance of the Alanine Aminotransferase (ALT) and the Alkaline Phosphate (ALP). 
The normal ranges for these three prognostic factors are provided in table S1 (see 
Supplementary Material). The importance of these variables in the treatment response 
suggests a close relationship to iron overload, liver damage and bone affectation.	 An 
adequate staging of newly diagnosed patients using this methodology will enable 
optimal treatment planning, which is particularly important in health care in order to 
find an optimum balance between treatment efficacy and drug toxicity.	
METHODS 
The present research work is a retrospective study in a cohort of 263 Caucasians 
who were diagnosed with classical Hodgkin Lymphoma in Asturias (Spain) that were 
enrolled in this study between 2002 and 2012. This study was approved by the 
institutional review boards of the different hospitals involved, and it was performed in 
accordance with the Helsinki Declaration of 1975. Besides, this study was approved by 
the Ethics Committee of the Principado de Asturias (date: 17th of January; Project 6th 
number 13). 
Staging definitions from the German Hodgkin Study Group (GHSG) were 
evaluated in this analysis. All patients were treated with the ABVD (doxorubicin, 
bleomycin, vinblastine, dacarbazine) regimen: 125 patients (47%) received involved 
field radiotherapy, 91 with early stage and 34 with advanced stage disease. Response to 
therapy was evaluated by physical and radiographic evaluation, including Computed 
Tomography (CT), and the follow up of the patients. In the last five years, PET scan 
was also included to assess treatment response. The treatment response was divided into 
3 categories according to international standards [13]: 237 of the patients were in 
Complete Remission (CR), 17 in Partial Remission (PR): and only in 9 of the cases, the 
disease progressed without any relevant change. This last category was named as 
Progressive Disease (PD).	 Table 1 describes the main characteristics of the patients: 
age, sex, stage at diagnosis, percentage of early favorable and early unfavorable and 
percentage of advanced disease depending on Hasenclever-Prognostic score. 
Progression-Free Survival (PFS) was calculated from the date of diagnosis to the 
date of progression, relapse or death by of any cause. Overall Survival (OS) was 
calculated from the date of diagnosis to the date of death from any cause or last follow-
up.  Overall and progression-free survival distribution curves were estimated using the 
product-limit method of Kaplan–Meier. The median PFS and OS for the entire group 
were respectively 150 and 160 months. The probabilities of PFS and OS at 7 years were 
57 and 76 %, correspondingly. 
Thirty-five clinical and biological variables were measured at diagnosis and 
before treatment. These variables were classified into 5 groups: biochemical, inmuno-
histochemical, Hodgkin Lymphoma specific, treatment specific, and host information. 
Table 2 shows the description of all these variables, boldfacing those that take discrete 
predefined values. Most of the variables had a sampling frequency higher than 90%. 
However, others were scarcely sampled, such as CRP (14%), immunoglobulins and 
Ki67 (20%). The need of imputing/filtering those variables has turned out to be a very 
important step in the modeling process. 
The problem addressed in this manuscript consists in building an efficient and 
simple machine methodology to predict HL first line treatment response with the 
highest predictive accuracy, and at the same time minimizing risk in the decisions. For 
that purpose we have used the response criteria defined by Cheson et al (2007) [13]. 
Patients were divided into three categories: Complete Remission (CR), defined as the 
disappearance of all evidence of disease; Partial Remission (PR) defined as regression 
of measurable disease and no new sites; and Progressive Disease (PD) defined as any 
new lesion or increase by 50% of previously involved sites. Four different classification 
problems were performed, to find the optimum way of separating these three classes.  
The machine learning methodology is explained in Appendix 1 (see Supplementary 
Material) and is composed by three main steps: 1. Pre-processing. 2. Feature Selection. 
3. k-NN design and risk analysis. 
Basically, the learning method consists, according to the parsimony principle, in finding 
the shortest subset of most discriminatory clinical variables (also called the reduced 
base of prognostic variables) to predict treatment response in HL patients. The clinical 
and biological variables are first ranked according to two different filter methods: 
Fisher’s ratio (FR) and Maximum Percentile Distance (MPD). In a second step, the 
predictive accuracy of the different ranked lists of prognostic variables is established by 
Leave-One-Out-Cross-Validation (LOOCV) experiment using a simple k-Nearest-
Neighbor (k-NN) classifier (Appendix 1 in Supplementary Material). This methodology 
has been successfully applied to predict risk of radiotherapy-related fatigue in prostate 
cancer patients using high dimensional expression data [14]. In this case, the challenge 
is not related to the dimension of the dataset, but to the heterogeneous degree of 
sampling of the different clinical variables. Besides, in this case the methodology 
incorporates the weights optimization of the k-NN classifier according to the Receiver 
Operating Characteristic (ROC) curve, in order to improve risk decision-making, that is, 
to provide a very high predictive accuracy with an optimum balance between the 
different rates of the confusion matrix (the true positive and false positive rates defining 
the corresponding ROC curve). Figure 1 shows a flow diagram explaining the 
methodology. 
Finally, we would like to point out that the aim of this work is not to numerically 
comparing different machine learning methods, but to introduce simple algorithms to 
select the shortest list of prognostic variables that could be easily interpreted by medical 
doctors, in order to improve the patient prognostic in HL treatment response, with its 
corresponding risk assessment. Particularly, we tried to avoid the use of black boxes 
that provide estimations without Medical Doctors’ understanding. As a matter of fact, 
this methodology can be easily implemented in any platform such as a spreadsheet (see 
Supplementary Material –HL treatementResponse_Predictor.xls-, and the corresponding 
explanation provided in Appendix 2). That said, the classifier that is proposed in this 
paper outperformed other more sophisticated classifiers that are proposed in the 
machine learning literature, highlighting the importance of selecting the correct 
prognostic variables.  
RESULTS 
Treatment response in HL is a difficult prediction problem. Aside from plasma 
EBV DNA [15], there is no predictive biomarker to bode the patient’s response to the 
corresponding treatment with a reliable accuracy. This classification problem is 
intrinsically highly unbalanced, mainly due to the discrete sampling of the samples 
(number of patients), and also due to the fact that a high percentage of the patients are 
cured from this kind of malignancy.  
The first modeling decision was to transform the analysis of treatment response 
into a binary classification problem (two-class problem) that admits a more reliable and 
stable solution than the corresponding value regression problem, that is, it is easier to 
predict if a patient is in complete or partial remission than predicting the value of the 
biological variables related to this fact. Besides, the prediction in binary classification 
problems allows for risk assessment through the analysis of the confusion matrix and 
the Receiving Operating Characteristic (ROC) curve. The confusion matrix consists of 4 
different groups: True Positives (TP), True Negatives (TN), False Positives (FP) and 
False Negatives (FN); whose definition depends on how the classification problem has 
been set up. From the confusion matrix, different rates can be calculated to understand 
the risk on the prediction: 
1. True Positive Rate or Sensitivity (TPR): measures the proportion of actual 
positives that are correctly predicted as such. 
2. True Negative Rate or Specificity (SPC): measures the proportion of negatives 
that are correctly predicted as such. 
3. False Positive Rate (FPR): fraction of false positives out of the total actual 
negatives. 
4. False Negative Rate (FNR): fraction of false negatives out of the total actual 
positives. 
5. False Discovery Rate (FDR): fraction of false positives out of the total actual 
positives. 
These rates could be used by the physicians in their decision-making process. A perfect 
classifier would have 100% sensitivity and specificity. 
The following comparisons were performed:  
1. CR vs. PR+PD 
2. CR+PR vs. PD and CR vs. PR 
3. CR vs. PR vs. PD 
Comments for the prognostic variables in comparisons 1 and 3 are given in 
Appendix 3 (see Supplementary Material), since we have obtained worse results. The 
most effective comparison was the second one, and it is composed of two main steps. In 
the first step (2.1 CR+ PR vs. PD), we established the differences between patients that 
experimented partial or complete remission (CR + PR, positive class) from those in 
which the disease progressed without any relevant change (PD, negative class). Then, a 
second comparison (2.2 CR vs. PR) is used to establish the differences between CR 
(positive class) and PR (negative class) patients.  
The best result was obtained by filtering out those variables having a sampling 
frequency lower than 30%, and imputing the rest. Besides, MPD (Maximum Percentile 
Distance) provided the shortest list of variables with the highest predictive accuracy. 
Table 3 shows the confusion matrix rates (TPR, TNR, FPR, FNR) for all the 
binary classifications (comparisons 1 and 2), together with the false discovery rate 
(FDR), and the LOOCV predictive accuracy (ACC). No weights optimization has been 
performed in this case, that is, the weights correspond are the inverse of the prior 
variability of the prognostic variables (see Appendix 1 Supplementary Material). Table 
4 shows the mean values of the three prognostic variables for the different groups of the 
confusion matrix, and the weights (W) used to define the distance criterion in the 
nearest-neighbor classifier. 
Comparison 2.1: CR + PR vs. PD 
In this comparison Serum Ferritin was the single selected prognostic variable 
(using MPD as feature selection) with a predictive accuracy of 95.82%. The SF mean 
value in the TN group (3288 ng/mL) is even higher than in the previous comparison, 
being the SF value in the TP group 266 ng/mL. Therefore, patients with Progressive 
Disease show a very clear inflammatory behavior as shown by the SF value at 
diagnosis. The TPR of this comparison is very high (98.43%), and the TNR is higher 
than in comparison 1 (22.22%). The TP and FP maximum and minimum SF values are 
closer to normal SF values (see table S1 of Supplementary Material). Conversely, the 
TN and FN corresponding SF signatures are extreme values.  
Comparison 2.2: CR vs. PR 
The best subset of prognostic variables for this case was found by MPD and was 
composed by SF, ALT and ALP, providing 92% of LOOCV predictive accuracy. The 
TPR is very high (97.89%) and the TNR is quite low (11.76%), that is, the difference 
between partial and complete remission is very hard to tell, and the classifier tends to 
assign the complete remission class in most of the cases. There is a big gap between SF 
mean levels of both TP (249 ng/mL) and TN (2401 ng/mL) groups. Moreover, FP (405 
ng/mL) and FN (2131 ng/mL) mean SF values are similar to the mean SF values of the 
TN and TP groups, respectively. The same happens with ALP, there is also a big 
difference between TP (116.8 U/L) and TN (376 U/L) values. The mean values in the 
FP (163.5 U/L) and FN (608.4 U/L) groups are also close to the TP and TN groups, 
which make those samples very difficult to hit using this k-NN classifier. SF and ALP 
have higher mean values in the TN group than in the TP group. However, in the case of 
ALT, the mean value in the TP group (23.7 U/L) is higher than in the TN group (18 
U/L). Moreover, the difference between these two groups is very low. The ALT mean 
value in the FN group (74.4 U/L) is closer to the TP group, instead of being closer to the 
TN group, as it should be expected. This is due to the presence of some PR patients 
with anomalously large ALT values.  
k-NN weights optimization  
Particle Swarm Optimization (PSO) of the weights of the k-NN classifier was 
performed in order to improve TNR figures, giving more importance to the fact of 
hitting the negative ones, that is, increasing TNR while the overall accuracy is also 
improved (TPR is not affected). Details about PSO are given in Appendix 1 (see 
Supplementary Material). 
Table 5 shows the TPR, TNR, FPR, FNR, FDR and Predictive Accuracy (Acc) 
obtained after weights optimization. TN rates were improved around 10% in 
comparisons 2.1, whilst in comparison 2.2 TP rate was improved around 1%. The 
overall accuracy was improved in all the cases around 1%. Table 6 shows the mean 
values for TP, TN, FP, FN and the optimized weights for the prognostic variables (W 
weights). It can be observed that values of the weights increased after optimization for 
all the prognostic variables. Therefore, it is possible to improve the quality of the 
prediction, and minimize risk on the decisions, by optimizing the weights that are 
initially provided by the distance criterion. 
CONCLUSIONS 
In this paper we presented an optimum strategy to predict treatment response in 
HL. Three main discriminatory prognostic variables aroused in this analysis: Serum 
Ferritin, ALT and ALP.  
Serum ferritin has been frequently used as a surrogate marker for systemic iron 
stores, but may be also elevated in specific circumstances without excess iron stores, 
such as in inflammation, correlating closely to the activity of the malignant lymphomas. 
Serum ferritin levels have been reported to be elevated in HL patients, in particular in 
advanced stages and during disease progression [16, 17]. Moreover, it has been 
proposed that the release of IL-6 stimulates the overproduction of hepcidin in the liver, 
which correlates with the iron restriction and contributes to anemia in HL [18]. In 
addition, the abundant microenvironment surrounding the neoplastic Hodgkin's and 
Reed-Sternberg cells may contribute to alterations in iron metabolism [19]. Besides, 
Serum Ferritin concentration closely follows the activity of the malignant lymphomas 
[20]. Other research work [21] has shown that levels of Serum Ferritin higher than 500 
ng/mL is an important marker for predicting poor survival outcomes for non-Hodgkin 
Lymphoma. Nevertheless, and up to our knowledge, Serum Ferritin levels have not 
been yet related to the treatment response of HL patients. 
Serum activity levels of ALT enzyme are routinely used as a biomarker of liver 
injury caused by drug toxicity, infection, alcohol and steatosis. ALT plays a key role in 
the intermediary metabolism of glucose and amino acids, and also participates in 
cellular nitrogen metabolism and liver gluconeogenesis. This cytosolic enzyme 
catalyzes the transfer of the α-amino group from alanine to α-ketoglutaric acid. Serum 
levels of ALT are normally low (10 to 40 U/L), but any type of liver cell injury may 
modestly increase the ALT levels. Levels greater than 500 U/L occur most often in 
people with hepatic diseases, such as viral hepatitis, ischemic liver injury (shock liver), 
toxin-induced liver damage and tumor infiltration of liver. Despite the association 
between greatly elevated ALT levels and hepatocellular diseases, the levels of ALT 
does not correlate with the extent of liver cell damage [22]. 
The Alkaline Phosphatase test (ALP) is used to detect liver disease or bone 
disorders. In conditions affecting the liver, damaged liver cells release-increased 
amounts of ALP into the blood. Further, any condition that affects bone growth or 
causes increased activity of bone cells can affect ALP levels in the blood. In Non-
Hodgkin Lymphomas, ALP is increased in patients with bone marrow affectation [23], 
thus reaching stage IV and worse prognosis. A recent study suggests that ALP together 
with Gamma-Glutamyl Transferase and Albumin may define advanced stages of HL 
[24]. Moreover, bone affectation is also associated to a high progression degree (HR: 
1,96) [25]. However, in a patient with fever of unknown origin (FUO), highly elevated 
Alkaline Phosphatase and normal/slightly elevated serum transaminase levels suggest 
the possibility of lymphoma [26-28].  
Overall, the results of this study shows that the combined use of these prognostic 
variables, SF, ALT and ALP, in a simple classifier allow to predict first line treatment 
response in HL patients with high accuracy; and confirms a close relationship between 
treatment response in HL, inflammation, iron overload and liver and bone damage.  
Particularly, the combination of feature selection methods (maximum percentile 
distance), risk assessment analysis (ROC curve) and global optimization (PSO) 
provides biomarker discovery that is easily implemented in spreadsheet. 
To conclude, detecting those HL patients who do not respond to the treatment at 
early stages may help improving their treatment. This study proposed a new prognostic 
analysis method, based on mathematical models that identify three simple prognostic 
variables currently gathered at diagnosis that may help detecting with high accuracy 
those HL patients with bad prognosis without any additional cost. 
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LIST OF CAPTIONS 
 
Figure 1: Flow diagram for the Hodgkin Lymphoma treatment response prediction model. The methodology is 
composed of 3 steps: 1. Filtering and Imputing data.  2. Feature Selection. 3. k-NN design and risk analysis. In each 
box the different sub steps are also detailed. 
	
